- Patients with episodic migraine who received intravenous (IV) eptinezumab reported significantly fewer migraine days in the 12 weeks after treatment than those who received a placebo.
Why this matters
- The migraine preventative benefit was reported as early as 1 day after treatment, and almost one-third of patients experienced a ≥75% decrease in migraine days during the first month.
- PROMISE-I study of 888 patients (aged 18-75 years) with a diagnosis of migraine.
- Outcomes: change in monthly migraine days (MMDs), ≥75% and ≥50% migraine responder rate.
- Funding: H. Lundbeck A/S, Copenhagen, Denmark.
- Patients treated with eptinezumab vs placebo were more likely to achieve ≥75% migraine response across 1-4 weeks:
- 30 mg: 9.8% (P=.0170).
- 100 mg: 10.5% (P=.0112).
- 300 mg: 11.3% (P=.0066).
- MMDs were lower with eptinezumab vs placebo from baseline across weeks 1-12:
- 30 mg: −4.0 (P=.0046).
- 100 mg: −3.9 (P=.0182).
- 300 mg: −4.3 (P=.0001).
- Placebo: −3.2.
- Steeper ≥75% and ≥50% decreases, respectively, in migraine rates with eptinezumab vs placebo across 1-12 weeks were seen:
- 30 mg: 24.70% (P=.0272) and 50.2% (P=.00064).
- 100 mg: 22.2% (P=.1126) and 49.8% (P=.0085).
- 300 mg: 29.7% (P=.0007) and 56.3% (P=.0001).
- Placebo: 16.2% and 37.4%.
- Limited geographical diversity.
- Small sample size.
Coauthered with Vijay Rathod, PhD